Blind Pew sends a black spot: the current haemoglobin controversy.
Two randomised controlled trials of anaemia management published in the last year have fuelled the current haemoglobin controversy and led the United States Food and Drug Administration to issue a public health advisory warning concerning the use of erythropoiesis-stimulating agents and target haemoglobin levels. There is much more to the haemoglobin controversy than purely target haemoglobin levels. This article seeks to outline some of the current issues involved.
Stevens
P E
PE
Department of Renal Medicine, Kent and Canterbury Hospital, Canterbury, UK. paul.stevens@ekht.nhs.uk
D000740:Anemia / Q000517:prevention & control; D017277:Drug Approval; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006454:Hemoglobins / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000503:physiopathology; D011356:Product Labeling; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins
D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin